NEW YORK, Jan. 25, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of GW Pharmaceuticals plc (“GW Pharmaceuticals”) (NASDAQ:GWPH) between December 4, 2014 and January 8, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to: http://zlk.9nl.com/gw-pharmaceuticals.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company lacked effective internal financial controls; (ii) the Company lacked effective controls over completeness and valuation of clinical trial accruals; and (iii) as a result of the foregoing, Defendants’ statements about GW Pharmaceuticals’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
In its 2015 Annual Report, GW Pharmaceuticals disclosed the discovery of a material weakness in its internal control over financial reporting for the year ended September 30, 2015. The Company noted that “management does not have sufficiently precise controls to evaluate the completeness and accuracy of the calculation of clinical trial accruals due to the incorrect allocation of expenditure to clinical studies.” On this news, GW Pharmaceuticals stock fell $3.55, or nearly 6%, to close at $56.31 per share on January 11, 2016.
If you suffered a loss in GW Pharmaceuticals you have until March 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/gw-pharmaceuticals.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 



